| Sponsor |
Therapeutic Area |
Target |
Actual |
Met |
Notes |
| Novotech |
Menopause |
20 |
35 |
| 10 screen failures |
| Solvay Pharmaceuticals |
Vaccines |
0 |
137 |
| Competitivie recruitment
Recruited 137 study participants in 3 weeks. |
| Bio Assetts |
Sciatica |
10 |
11 |
| Other sites are slow to recruit - ER will continue to recruit above the set target |
| Bayer |
Blood Clot Prevention |
15 |
5 |
| Difficult study to enrol into - recruitment slow world wide. |
| Merck Sharp & Dohme |
Type 2 Diabetes & Hypertension |
5 |
5 |
| |
| CBio |
Rheumatoid Arthritis |
10 |
15 |
| |
| Merck Sharp & Dohme |
Migraine |
5 |
5 |
| |
| Novotech |
Rhinitis |
30 |
30 |
| |
| CBio |
Rheumatoid Arthritis |
6 |
8 |
| |
| Eli Lilly |
Osteoporosis Vertebral # |
8 |
11 |
| still recruiting |
| Human Genome Sciences |
Systemic Lupus Erythematosus |
5 |
11 |
| |
| Bristol-Myers Squibb |
Systemic Lupus Erythematosus |
5 |
3 |
| Inclusion criteria required subjects to flare - difficult to capture as subjects often attend physician after the flare |
| Genzyme |
Osteoarthritis |
80 |
82 |
| abstract at ESSKA and EULAR |
| Johnson & Johnson |
Low Back Pain |
5 |
2 |
| Problems with study logistics ceased recruitment |
| Merck Sharp & Dohme |
HPV VACCINE |
40 |
40 |
| |
| Auxilium |
Dupuytren's Contracture |
20 |
41 |
| |
| Boehringer Ingelheim |
Chronic Obstructive Pulmonary Disease |
10 |
11 |
| |
| Boehringer Ingelheim |
Type 2 Diabetes & Hypertension |
5 |
1 |
| Site brought on late to help recruitment - study closed within one month of set-up |
| Merck Sharp & Dohme |
Phase 4 Marketing Survey Cholesterol |
50 |
22 |
| Ceased recruiting due to cost involved |
| Auxilium |
Dupuytren's Contracture |
8 |
3 |
| Study closed - study drug stability in question - new batch to be manufactured.
Study closed - new protocol developed. |
| Optipharm |
Weight Loss |
50 |
50 |
| |
| Metabolic |
Weight Loss |
30 |
50 |
| |
| GlaxoSmithKline |
Type 2 Diabetes |
10 |
12 |
| |
| Aventis |
Type 2 Diabetes |
25 |
25 |
| |
| Aventis |
Type 2 Diabetes |
30 |
30 |
| |
| AstraZeneca |
Type 2 Diabetes |
5 |
21 |
| |
| AstraZeneca |
Type 2 Diabetes |
10 |
5 |
| |
| Wyeth |
Rheumatoid Arthritis Health Economic Study |
50 |
50 |
| |
| Wyeth |
Rheumatoid Arthritis |
8 |
19 |
| |
| Wyeth |
Rheumatoid Arthritis |
3 |
3 |
| |
| Wyeth |
Rheumatoid Arthritis |
5 |
7 |
| |
| Roche |
Rheumatoid Arthritis |
6 |
7 |
| |
| Roche |
Rheumatoid Arthritis |
7 |
7 |
| |
| Roche |
Rheumatoid Arthritis |
5 |
8 |
| |
| Merck Sharp & Dohme |
Rheumatoid Arthritis |
10 |
12 |
| |
| Centocor |
Rheumatoid Arthritis |
10 |
26 |
| Top Site Globally |
| Centocor |
Rheumatoid Arthritis |
8 |
11 |
| |
| CBio |
Rheumatoid Arthritis |
8 |
10 |
| |
| Bristol-Myers Squibb |
Rheumatoid Arthritis |
8 |
10 |
| |
| Boehringer Ingelheim |
Rheumatoid Arthritis |
6 |
8 |
| |
| Amgen |
Rheumatoid Arthritis |
8 |
8 |
| |
| Amgen |
Rheumatoid Arthritis |
8 |
8 |
| |
| GlaxoSmithKline |
Restless Legs Syndrome |
6 |
11 |
| |
| Serono |
Psoriasis |
5 |
4 |
| Study closed early |
| CBio |
Psoriasis |
24 |
24 |
| |
| GlaxoSmithKline |
Post Herpetic Neuralgia |
6 |
6 |
| |
| PRA International |
Parkinson's Disease |
6 |
8 |
| |
| Johnson & Johnson |
Pain - End Stage Joint Disease |
6 |
6 |
| |
| Novartis |
Osteoarthritis |
20 |
31 |
| |
| Aventis |
Osteoarthritis |
20 |
47 |
| |
| Novartis |
Osteoarthritis |
6 |
5 |
| |
| Merck Sharp & Dohme |
Osteoarthritis |
20 |
16 |
| Study closed 6 weeks early, booked pts. not allowed to be screened |
| GlaxoSmithKline |
Osteoarthritis |
12 |
18 |
| |
| Genesis Biomedical |
Osteoarthritis |
100 |
107 |
| Top site in Australia |
| Boehringer Ingelheim |
Osteoarthritis |
20 |
38 |
| |
| AstraZeneca |
Osteoarthritis |
6 |
6 |
| |
| AstraZeneca |
Non-ulcer Dyspepsia |
30 |
31 |
| |
| Merck Sharp & Dohme |
Low Back Pain |
8 |
8 |
| |
| Sanofi Aventis |
Insomnia |
10 |
10 |
| |
| Sanofi Pasteur |
Influenza Vaccine |
90 |
91 |
| |
| PPD |
Immune Thrombocytopenic Purpura |
5 |
3 |
| Insufficient study supplies to site delayed recruitment |
| Merck Sharp & Dohme |
Hypertension |
8 |
8 |
| |
| AstraZeneca |
Gastroenterology |
20 |
25 |
| |
| Eli Lilly |
Fibromyalgia |
10 |
18 |
| |
| Arakis |
Fibromyalgia |
10 |
17 |
| Top site globally |
| Merck Sharp & Dohme |
Dyslipidaemia |
15 |
17 |
| |
| Merck Sharp & Dohme |
Dyslipidaemia |
18 |
18 |
| |
| Aventis |
Diabetes |
8 |
2 |
| |
| Aventis |
Diabetes |
8 |
8 |
| |
| AstraZeneca |
Chronic Obstructive Pulmonary Disease |
5 |
3 |
| Difficulty recruiting closed site |
| Merck Sharp & Dohme |
Cardiac Endpoint Study |
50 |
100 |
| Top Site Globally |
| AstraZeneca |
Asthma |
6 |
13 |
| |
| AstraZeneca |
Asthma |
20 |
22 |
| |
| AstraZeneca |
Asthma |
6 |
18 |
| |
| Boehringer Ingelheim |
Anticoagulant |
16 |
15 |
| Orthopaedic referrals ceased due to venogram |
| Boehringer Ingelheim |
Anticoagulant |
18 |
17 |
| Orthopaedic referrals ceased due to venogram |
